Insider · CIK 0001337845
Vikas Sinha
officerdirectorownercfo
Files at VRNA (Verona Pharma plc), SRRK (Scholar Rock Holding Corp), KLRS (Kalaris Therapeutics, Inc.). First filing Oct 23, 2024, latest May 22, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $3.1M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KLRS: Kalaris Therapeutics, Inc.
KLRSOct 9, 2026 · close 2.36
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Verona Pharma plc | $1.5M 160,000 shares | -68% | - | |
| 40Moderate | Verona Pharma plc | $1.4M 160,000 shares | -82% | - | |
| 12Weak | Verona Pharma plc | $178k 20,000 shares | -22% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $3,053 303 shares | -1% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $1,226 129 shares | -0% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $431 979 shares | -0% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $1,748 3,186 shares | -0% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $4,442 5,136 shares | -0% | - | |
| 30Weak | Kalaris Therapeutics, Inc. | $2,649 3,428 shares | -0% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +160,000 | $0.50 | $81k | 234,440 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +120,384 | $1.70 | $205k | 194,824 | May 22, 2025 |
| May 20, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -160,000 | $9.39 | $1.5M | 74,440 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -120,384 | $8.92 | $1.1M | 74,440 | May 22, 2025 |
| May 20, 2025 | VRNA Verona Pharma plc | MOption exercise Share Options (Right to Buy)derivative10b5-1 | -160,000 | $0.00 | $0 | 384 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +39,616 | $0.50 | $20k | 114,056 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -39,616 | $8.92 | $353k | 74,440 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Share Options (Right to Buy)derivative10b5-1 | -120,384 | $0.00 | $0 | 0 | May 22, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Share Options (Right to Buy)derivative10b5-1 | -39,616 | $0.00 | $0 | 160,384 | May 22, 2025 |
| May 2, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Stock Option (Right to Buy)derivative | +110,067 | $0.00 | $0 | 110,067 | May 6, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +15,048 | $1.70 | $26k | 89,488 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -15,048 | $8.92 | $134k | 74,440 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +4,952 | $0.50 | $2,495 | 79,392 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -4,952 | $8.92 | $44k | 74,440 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Share Options (Right to Buy)derivative10b5-1 | -15,048 | $0.00 | $0 | 80,952 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Share Options (Right to Buy)derivative10b5-1 | -4,952 | $0.00 | $0 | 195,048 | May 1, 2025 |
| Apr 27, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 100,000 | Apr 29, 2025 |
| Apr 25, 2025 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitsderivative | +96,000 | $0.00 | $0 | 96,000 | Apr 29, 2025 |
| Apr 27, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 600,000 | Apr 29, 2025 |
| Feb 21, 2025 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -303 | $10.08 | $3,053 | 49,129 | Feb 24, 2025 |
| Jan 23, 2025 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -116 | $9.45 | $1,097 | 49,445 | Jan 27, 2025 |
| Jan 23, 2025 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -13 | $9.94 | $129 | 49,432 | Jan 27, 2025 |
| Jan 10, 2025 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -979 | $0.44 | $431 | 1,139,915 | Jan 13, 2025 |
| Nov 19, 2024 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -3,186 | $0.55 | $1,748 | 1,140,894 | Nov 20, 2024 |
| Nov 5, 2024 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -5,136 | $0.86 | $4,442 | 1,144,080 | Nov 6, 2024 |
| Oct 21, 2024 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -1,546 | $0.78 | $1,204 | 1,151,098 | Oct 23, 2024 |
| Oct 22, 2024 | KLRS Kalaris Therapeutics, Inc. | SOpen-market sale Common Stock | -1,882 | $0.77 | $1,445 | 1,149,216 | Oct 23, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.